26th March 2019 Content supplied by: Rebiotix, Inc.
Microbiota-based Therapeutics on Clostridioides difficile Infection Patient Microbiomes
Rebiotix Inc., a Ferring company,presented analyses of clinical samples collected during two of the company’s completed phase 2 clinical trials for the prevent of recurrent Clostridioides difficile infection, and the contribution of these data to further develop the company’s prototype Microbiome Health Index (MHI) platform metric during the recent Gut Microbiota for Health World Summit.
“The MHI platform is an integral part of furthering our understanding of the impact of the gut microbiome on human health,” said Dr. Ken Blount, Chief Scientific Officer at Rebiotix. “Through our extensive research programs that have grown from our clinical trials, we are unveiling new facets of the microbiome and its correlation with conditions like Clostrioides difficile infection. We are excited to continue to share our findings with colleagues in the field, as we believe these data are critical to further our collective knowledge concerning the potential of microbiota-based therapeutics.”
The MHI platform, part of the research arm of the company’s microbiota-based MRT™ drug platform, continues to expand opportunities to investigate changes in disrupted gut microbial ecosystem of patients before and after intervention with the MRT drug formulations currently under clinical investigation.
Rebiotix has a diverse pipeline of investigational drug products built on its pioneering microbiota-based MRT™ drug platform. The MRT platform is a standardised, stabilised drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via ready-to-use and easy-to-administer formats. The lead drug candidate, RBX2660, is currently in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the US FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized, non-frozen, oral capsule part of a recently completed investigator-sponsored Phase 1 trial for the prevention of recurrent C. diff infection.
For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com.
Date Published: 26th March 2019
Source article link: Rebiotix, Inc.